PharmaBoardroom

John M. O’Brien, recently appointed president and CEO of the US National Pharmaceutical Council, calls for innovation in benefit design reform to…

Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for…

In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the…

Patient advocate and regular PharmaBoardroom contributor Monica Weldon examines how healthcare’s data revolution has thus far largely ignored the…

The latest from US health care policy, including the Senate budget deal funding for a range of major health care priorities; Biden’s proposed…

Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the…

Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual…

With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease…

Taking the example of music's effect on Alzheimer's disease patients, John G Singer makes the case for a more holistic approach to healthcare;…

AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment,…

Writing in the May edition of DIA’s Global Forum magazine, Erica Lyons, Sarrit Kovacs, Matthew Kowalik, and Jessica Lee from the Division of…

The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the…